Laurie D. Stelzer
2016
In 2016, Laurie D. Stelzer earned a total compensation of $1.9M as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics, a 51% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $207,000 |
|---|---|
| Option Awards | $500,013 |
| Salary | $435,000 |
| Stock Awards | $749,997 |
| Other | $8,643 |
| Total | $1,900,653 |
Stelzer received $750K in stock awards, accounting for 39% of the total pay in 2016.
Stelzer also received $207K in non-equity incentive plan, $500K in option awards, $435K in salary and $8.6K in other compensation.
Rankings
In 2016, Laurie D. Stelzer's compensation ranked 5,114th out of 14,075 executives tracked by ExecPay. In other words, Stelzer earned more than 63.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,114 out of 14,075 | 64th |
Division Manufacturing | 1,825 out of 5,486 | 67th |
Major group Chemicals And Allied Products | 580 out of 1,900 | 70th |
Industry group Drugs | 435 out of 1,543 | 72nd |
Industry Biological Products, Except Diagnostic Substances | 76 out of 287 | 74th |
Source: SEC filing on March 24, 2017.
Stelzer's colleagues
We found four more compensation records of executives who worked with Laurie D. Stelzer at Halozyme Therapeutics in 2016.